key: cord-0985199-n4u0vm61 authors: Fillmore, Nathanael R; La, Jennifer; Szalat, Raphael E; Tuck, David P; Nguyen, Vinh; Yildirim, Cenk; Do, Nhan V; Brophy, Mary T; Munshi, Nikhil C title: Prevalence and outcome of COVID-19 infection in cancer patients: a national Veterans Affairs study date: 2020-10-08 journal: J Natl Cancer Inst DOI: 10.1093/jnci/djaa159 sha: 5896fe5d6a45b35398ae5402db9dd4efc75dcc96 doc_id: 985199 cord_uid: n4u0vm61 BACKGROUND: Emerging data suggest variability in susceptibility and outcome to COVID-19 infection. Identifying risk-factors associated with infection and outcomes in cancer patients is necessary to develop healthcare recommendations. METHODS: We analyzed electronic health records of the US Veterans Affairs healthcare system and assessed the prevalence of COVID-19 infection in cancer patients. We evaluated the proportion of cancer patients tested for COVID-19 who were positive, as well as outcome attributable to COVID-19, and stratified by clinical characteristics including demographics, comorbidities, cancer treatment and cancer type. All statistical tests are two-sided. RESULTS: Of 22914 cancer patients tested for COVID-19, 1794 (7.8%) were positive. The prevalence of COVID-19 was similar across age. Higher prevalence was observed in African-American (AA) (15.0%) compared to White (5.5%; P<.001) and in patients with hematologic malignancy compared to those with solid tumors (10.9% vs 7.8%; P<.001). Conversely, prevalence was lower in current smokers and patients who recently received cancer therapy (<6 months). The COVID-19 attributable mortality was 10.9%. Higher attributable mortality rates were observed in older patients, those with higher Charlson comorbidity score, and in certain cancer types. Recent (<6 months) or past treatment did not influence attributable mortality. Importantly, AA patients had 3.5-fold higher COVID-19 attributable hospitalization, however had similar attributable mortality as White patients. CONCLUSION: Pre-existence of cancer affects both susceptibility to COVID-19 infection and eventual outcome. The overall COVID-19 attributable mortality in cancer patients is affected by age, comorbidity and specific cancer types, however, race or recent treatment including immunotherapy does not impact outcome. The COVID-19 infection first reported in China, in December 2019 1 , has now spread worldwide affecting all demographics and regions. The emerging data suggests variability in susceptibility to the infection and ultimately outcome. A number of patient related factors, socioeconomic conditions, racial and ethnic differences and several comorbidities including obesity, diabetes and cardiovascular diseases have been associated with higher susceptibility and/or risk of mortality. [2] [3] [4] [5] The relatively higher transmission rate and associated greater risk of adverse outcome has highlighted the need to understand the epidemiologic characteristics of COVID-19 prevalence, and the risk factors associated with poor outcome and death, in order to establish the best possible public health policies. Cancer patients are considered to be at higher risk of infection. This risk varies with functional status of the patient, cancer type, and/or treatment modalities utilized. 6, 7 Thus, along with reducing exposure to the virus, other prophylactic as well as cancer-related risk factors may need to be addressed to decrease susceptibility to COVID-19 infection or to mitigate related complications in cancer patients. Small epidemiologic studies mainly from China and USA have also reported increased rates of death in cancer patients related to COVID-19. 8, 9 These observations have informed some changes and re-organization of cancer care worldwide 10 but larger studies are needed to understand the comprehensive cancerrelated issues with COVID-19 infection. Here we investigated the prevalence and outcome of COVID-19 infection among cancer patients in a large cohort of patients from the nationwide Veterans Affairs (VA) healthcare system. This analysis was conducted using data from the VA Corporate Data Warehouse, which centralizes EHR data for patients seen at VA facilities nationwide. The study population is defined as veterans with cancer who were tested for COVID-19 at the VA. Cancer patients were identified as patients with at least one occurrence of an International Classification of Diseases (ICD) code for cancer between January 1, 2010 and May 4, 2020. 26 Non-melanoma skin cancer and benign tumors were excluded. This study was performed under a protocol approved by the VA Boston Healthcare System Research and Development Committee. Patient demographics, COVID-19 laboratory tests, comorbidities, cancer type, cancer treatment, and outcomes were identified through structured data in the EHR. Patients were considered positive for COVID-19 if they had at least one positive test result, and negative if all COVID-19 test results were negative. Based on manual review of laboratory test names, COVID-19 tests were identified using regular expressions matching either ".*covid.*" or ".*corona.*2019.*", and excluding ".*not.covid.19.*". COVID-19 tests that were cancelled or did not have a positive or negative result recorded were excluded from consideration. The Charlson comorbidity index and presence of individual comorbidities were derived from ICD codes in the year prior to each patient's first COVID-19 test using the comorbidity package in R. 13 test. Missing data existed for race, ethnicity, and smoking status and was coded as a separate level in all analyses. We evaluated the proportion of COVID-19 positive patients among those tested, along with 95% confidence intervals, and stratified by demographics, comorbidities, cancer treatment and cancer type. We also evaluated the proportion of patients experiencing each outcome among COVID-19 positive and negative patients, and defined the 7 COVID-19 attributable risk of each outcome as the difference of these two proportions. We used chi-squared tests to assess differences in proportion. Odds ratio (OR) as to COVID-19 positive status by cancer type was assessed using univariate and multivariate logistic regression, adjusting for race, ethnicity, and smoking status in the multivariate models. All statistical tests were two-sided and a P value of less than .05 was considered statistically significant. We identified 22914 patients with history of cancer who were tested for COVID-19 infection on or before May 4, 2020, of whom 1794 patients (7.8%) reported positive ( Figure 1A) . The prevalence of COVID-19 among those tested was similar across all ages (<50 years to ≥80years; P=.16), although older patients with cancer were tested for COVID-19 more frequently (Supplementary Table 1 ). Importantly, there was a statistically significant difference in prevalence of infection across race and ethnicity, with 15.0% of African Americans (AA) but only 5.5% of White patients testing positive for COVID-19 (P<.001), and 10.9% of Hispanic/Latino patients vs 7.7% of non-Hispanic/Latino patients testing positive (P<.001). Higher prevalence was observed in patients with hematologic malignancy compared to those with solid tumors (10.9% vs 7.8%; P<.001). We also observed a statistically significantly lower prevalence in cancer patients who were current smokers compared to former smokers or those who never smoked (5.3% vs 9.5%; P<.001). Compared to the overall sample (7.8% positive), there was a small but statistically significant negative association between susceptibility to 8 COVID-19 and concomitant congestive heart failure (6.7% positive; P<.001), peripheral vascular disease (6.5%; P<.001), chronic obstructive pulmonary disease (6.3%; P<.001), and moderate/severe liver disease (5.1%; P=.02). Higher body mass index (BMI) was associated with increased prevalence of infection (P<.001). During the period of observation, COVID-19 was much more frequent in the North Atlantic (14.8%) than other regions (6.3% Continental, 7.9% Midwest, 2.4% Pacific, 3.2% Southeast; P<.001). Differences in susceptibility across race persisted within each region and in individual VA hospital sites (Supplementary Tables 2 and 3) . We further investigated cancer types and prevalence of COVID-19 ( Figure 1B Table 4 ). Although the univariate analysis showed that patients with prostate cancer had a higher risk of COVID-19 infection, this was no longer the case after adjustment, suggesting the higher prevalence observed in prostate cancer may be affected by race, ethnicity, and/or smoking status. On the other hand, patients 9 with esophageal cancer, HCC, lung cancer, lymphoma, SCCHN, bone cancer, melanoma, and other cancers continued to have a lower risk of COVID-19 infection even after adjusting for these factors. Next, we evaluated the impact of active cancer treatment on susceptibility to COVID-19 infection and observed that patients receiving cancer therapy within the last 6 months had statistically significantly lower prevalence (6.2%) of COVID-19 compared to those who received therapy >6 months ago (7.8%) or never received therapy (8.1%; P=.002). Moreover, compared to the overall cohort (7.8%), patients receiving immune checkpoint inhibitors (2.7%, P<.001) or chemotherapy (4.6%, P<.001) within the last 6 months had statistically significantly lower prevalence of COVID-19 while patients on hormonal therapy (8.1%, P=.76) or targeted therapy (6.6%, P=.11) did not have statistically significantly different prevalence. We next evaluated the impact of COVID- 19 Figure 2 ). 10 To further assess the impact of patient and disease-related features on COVID-19 attributable outcomes, we evaluated each of the demographic and comorbidity strata described above (Figure 3A and 4A) Table 6 ). Outcomes were variable based on type of cancer (Figures 3B and 4B) We investigated a large cohort of cancer patients evaluated for COVID-19 at the VA Healthcare System from across the United States in order to identify risk factors for COVID-19 susceptibility and outcomes in cancer patients. The overall frequency of COVID-19 positivity was 7.8% of tested patients. As of May 16th, 2020, according to the United States Center for Disease Control, the national positivity rate for COVID-19 infection in the US among patients aged of 18 and older is 13.5% with 126,627 positive patients out of 928,366 tested patients. 16 Thus, the prevalence of COVID-19 among cancer patients appeared to be lower than in the general population. However, the real prevalence of COVID-19 remains uncertain, as a substantial number of patients are not 12 or have not been tested, particularly in the context of asymptomatic disease. Nevertheless, the observed lower prevalence of COVID-19 in cancer patients might be explained either by higher access to testing within the VA healthcare system and/or higher rates of testing in cancer patients in general. Perhaps the most striking observation in our data is the statistically significant racial and ethnic disparity in prevalence of COVID-19 infection. African-American Tables 2 and 3 ) rules out the possible role of regional conditions in explaining this difference. COVID-19 was more frequent among patients with prostate cancer which is also more frequent in African-American patients, 20 although after adjusting for race, ethnicity, and smoking status, this difference is no longer observed. The possible explanations requiring further investigation include socio-economic factors or genetic predisposition. Importantly, although AA cancer patients were more frequently admitted to the hospital, with equal access to care in the VA healthcare system, similar mortality rate was observed between AA and White cancer patients. Similar trend was also observed in Hispanic/Latino population. These results suggest distinct factors modulating COVID-19 susceptibility and the related-outcome. The statistically significantly reduced prevalence of COVID-19 infection in cancer patients with current smoking history, compared to those who have quit smoking or 13 never smoked, is intriguing. This observation is also confirmed by observed reduced frequency of COVID-19 infection among patients with lung (4.3%, P<.001), SCCHN (5.5%, P<.001), and urothelial (6.5%, P=.01) cancers, all malignancies associated with smoking. These differences might also be related to race or ethnicity (Supplementary Tables 5 and 6 ), or to socio-economic factors. An earlier preliminary report has also suggested association of active smoking with lower rates of COVID-19 infections. 21 This negative association requires further investigation. The role of nicotine, local epithelial cell changes or inflammatory environment may play a role. 22, 23 We did not observe a substantial impact of cardiopulmonary and other comorbidities as well as age of patients on rate of infection (Figure 1) , which may suggest that pre-existence of cancer could outweigh the other comorbidities in regard to susceptibility to COVID-19. Moreover, it is possible that sick patients and patients under active cancer treatment may have been more cautious and thus less exposed to COVID-19, and this may affect the vulnerability. While we are unable to directly quantify severity of cancer illness in our dataset, we included two proxies for severity of disease that are available: whether or not each patient was recently treated for cancer (≤6 months ago), treated >6 months ago, or never treated with systemic therapy, which serves to some extent as a proxy for severity; and the Charlson score which reflects severity of overall health condition prior to COVID-19 diagnosis. Our analysis reveals statistically significantly lower rate of infection in patients treated ≤6 months ago, though no difference in COVID-19 attributable mortality or other outcomes, and higher rates of infection in patients with higher Charlson score was observed. Outcome of cancer patients infected by COVID-19 was characterized by higher 14 rates of mortality. Although the frequency of COVID-19 positivity was lower in patients receiving cancer related therapy within 6 months of the COVID-19 infection, the overall mortality was not statistically significantly different in comparison to no treatment or treatment prior to 6 months groups. These mortality rates are higher than the mortality rates reported in the global population 8, 24 and confirm higher vulnerability of cancer patients to COVID-19 infection. Therapies including conventional chemotherapy, targeted therapies with small molecules or monoclonal antibodies were associated with higher mortality rates in this study. ICI treatment was associated with a lower rate of infection, however, only a small number of patients are in this group suggesting both caution in interpreting this data and also a need for further focused investigation in patients receiving ICI therapy and with COVID-19 positivity. The lower mortality rate in patients receiving this treatment confirms the recent report about the impact of this therapy on COVID-19 outcome. 25 Higher rates of mortality were observed in elderly patients, patients with higher Charlson score, underweight patients and patients with comorbidities, mainly cardiovascular and renal disease (Figure 3) . While hematological malignancies were associated with higher rates of infection, similar COVID-19 attributable mortality was observed in comparison to solid malignancies (Figure 3 and Supplementary Table 7) . Fatality rate related to each cancer type was variable with breast, male genital, acute leukemia and thyroid cancer being associated with highest rate of COVID-19 related mortality (Figure 3) . Our study has several limitations. First, the veteran population is primarily male and hence the study represents various trends and associations whose interpretations are restricted to male. Second, patients tested outside the VA system would not be 15 included in this analysis. However, this number is likely to be very small as most patients who get cancer care in the VA do return for their healthcare needs to the VA. Third, it is possible that analyses are confounded by indication for testing. However, we believe that our comparison of those who tested positive to those who tested negative remains relevant, especially because COVID-19 testing criteria at VA hospitals was informed by centralized guidance from the VA Central Office, increasing consistency of testing criteria nationally. 27 In conclusion, the presence of cancer changes the susceptibility to COVID-19 infection and affects overall outcome. The overall disease behavior is modulated by patient-related as well as cancer-related factors which needs to be considered in development of COVID-19 preventative strategies as well as modulation of cancer therapies to optimize the patient care. Importantly, having equal access to care is an important component to improving overall outcome. A Novel Coronavirus from Patients with Pneumonia in China Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis Clinical Characteristics of Covid-19 in New York City Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline Incidence of Infection-related mortality in cancer patients: Trend and survival analysis Clinical Characteristics of Coronavirus Disease 2019 in China Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov COVID-19 More Frequent, Severe in Cancer Patients. Cancer Discov comorbidity: An R package for computing comorbidity scores Validating the use of veterans affairs tobacco health factors for assessing change in smoking status: accuracy, availability, and approach Disparities In Outcomes Among COVID Patients In A Large Health Care System In California Hospitalization and Mortality among Black Patients and White Patients with Covid-19 Prostate cancer in men of African origin Current Smoking is Not Associated with COVID-19 COVID-19 and Nicotine as a Mediator of ACE-2 Is Nicotine the Hidden Link? World Health Organization. Coronavirus disease (COVID-2019) situation reports Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov Cancer incidence among patients of the U.S. Veterans Affairs Health Care System Response Plan: Incident-specific Annex to the VHA High Consequence Infection (HCI) Base Plan. Version The data underlying this article cannot be shared publicly due to VA policy. The data will be shared on reasonable request to the corresponding author.